<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30315" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Calcium Channel Blocker Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chakraborty</surname>
            <given-names>Rebanta K.</given-names>
          </name>
          <aff>Steward Medical\Good Samaritan Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hamilton</surname>
            <given-names>Richard J.</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebanta Chakraborty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Hamilton declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30315.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Calcium channel blockers (CCBs) are among the most commonly used cardiovascular drugs in the adult population. Like most other medications, when calcium channel blockers are taken beyond the appropriate recommended dosage, they can have untoward toxicities with a wide range of complications that can even be fatal. This activity discusses their use to treat a wide array of clinical conditions including hypertension, supraventricular tachycardia, vasospasm, and migraine headaches.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the epidemiology of calcium channel blocker toxicity.</p></list-item><list-item><p>Outline the anticipated presentation of a patient with calcium channel blocker toxicity.</p></list-item><list-item><p>Summarize the common complications of treatment of calcium channel blocker toxicity.</p></list-item><list-item><p>Identify some interprofessional team strategies for improving care coordination and communication amongst interprofessional team members to improve the outcome of patients with calcium channel blocker toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30315&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30315">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30315.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Calcium channel blockers (CCBs) are among the most commonly used cardiovascular drugs in the adult population. They are used to treat a&#x000a0;broad array of clinical conditions, including hypertension, supraventricular tachycardia, vasospasm, and migraine headaches.&#x000a0;</p>
      </sec>
      <sec id="article-30315.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Accidental over-ingestion, suicidal ingestion, and exploratory ingestion in children can all lead to severe toxicity. Therapeutic use can lead to toxicity through drug interactions with other cardiac medications or increased drug exposure because of interference with metabolism or elimination. Poisoning with these agents can have severe hemodynamic effects and be fatal.<xref ref-type="bibr" rid="article-30315.r1">[1]</xref></p>
      </sec>
      <sec id="article-30315.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>American Poison Control Centers have reported cardiovascular drugs as the third fastest-growing category of substance exposures. The American Association of Poison Control Centers (2011) reported 11,764 CCB overdoses in adults, second only to beta-blockers in several overdose deaths from cardiovascular medications (reported at 78 deaths).<xref ref-type="bibr" rid="article-30315.r2">[2]</xref>&#x000a0;Calcium channel blockers and beta-blockers accounted for most deaths. Verapamil and propranolol were the most commonly implicated agents. However, cases may be&#x000a0;under-reported.<xref ref-type="bibr" rid="article-30315.r3">[3]</xref></p>
      </sec>
      <sec id="article-30315.s5" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Calcium channel blockers in all their subtypes target the L-type voltage-gated calcium channels. L type voltage-gated calcium channels are predominant in the following sites and roles:</p>
        <p>Depolarization of the sinoatrial node (SA) and impulse propagation through the atrioventricular node (AV). Calcium entry during the plateau phase of the action potential in myocardial cells releases calcium from the sarcoplasmic reticulum to the cytosol, triggering myocardial contraction. Contraction strength is directly proportional to intracellular calcium concentration, allowing actin and myosin to interact. Cytosolic calcium concentration mediated by membrane gated influx of calcium is responsible for maintaining vascular smooth muscle tone. The influx of calcium is also responsible for insulin secretion. All CCBs are very well absorbed orally across the subtypes, undergo extensive hepatic first-pass metabolism, are lipophilic, bind readily to plasma proteins, and have a large volume of distribution (&#x000a0;&#x0003e; 2 liters/kg). Elimination by hemodialysis or hemofiltration is ineffective.</p>
        <p>At higher doses clearance slows, because hepatic clearance changes from first-order to zero-order kinetics.</p>
        <p>Conventionally used CCBs belong to three main chemical classes, with each subclass having differing affinities for cardiac tissue and vascular smooth muscle:</p>
        <list list-type="bullet">
          <list-item>
            <p>Phenylalkylamines (verapamil)</p>
          </list-item>
          <list-item>
            <p>Benzothiazepines (diltiazem)</p>
          </list-item>
          <list-item>
            <p>Dihydropyridines (nifedipine, amlodipine, felodipine, isradipine, nicardipine, nimodipine)</p>
          </list-item>
        </list>
        <p>Verapamil has a strong affinity for both myocardium and vascular smooth muscle. It suppresses cardiac contractility, SA nodal automaticity, AV nodal conduction and causes potent vasodilation. Diltiazem has a similar range of effects as verapamil with less vasodilation; its effect is more potent on chronotropic action. Dihydropyridines are very effective vasodilators but exert less influence on cardiac pacemakers and myocardial contractility.<xref ref-type="bibr" rid="article-30315.r4">[4]</xref><xref ref-type="bibr" rid="article-30315.r5">[5]</xref><xref ref-type="bibr" rid="article-30315.r6">[6]</xref>&#x000a0;</p>
        <p>With significant overdoses, the serum and tissue concentration of these drugs are so excessive that the pharmacological difference in affinity and action between subclasses is overwhelmed. Thus, both verapamil and diltiazem causes significant bradycardia, hypotension, conduction disturbances, and escape rhythms. Nifedipine triggers hypotension and reflex sinus tachycardia.<xref ref-type="bibr" rid="article-30315.r7">[7]</xref> Calcium channel blockers of all subclasses reduce pancreatic insulin secretion and induce end-organ insulin resistance, causing hyperglycemia. Additionally,&#x000a0;CCBs interfere with calcium-stimulated mitochondrial action and glucose catabolism; this results in lactate production and ATP hydrolysis, contributing to acidosis.<xref ref-type="bibr" rid="article-30315.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30315.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Depending on age, health, co-ingestion of other cardiovascular medications, and the magnitude of toxic ingestion, the presentation may vary from asymptomatic to sudden cardiovascular collapse and death. Ingestion of toxic&#x000a0;immediate-release CCB formulations&#x000a0;is&#x000a0;expected to have an onset of effect within 2 to 3 hours of ingestion, with all patients manifesting some&#x000a0;symptoms within 6 hours.<xref ref-type="bibr" rid="article-30315.r9">[9]</xref> Toxicity can be delayed up to 16 hours after the ingestion of sustained-release formulations.</p>
        <p>Initial symptoms may be as nonspecific as dizziness, fatigue, and lightheadedness, and in severe toxicities, it may rapidly decline to alter mental status, coma, and fatal shock.</p>
      </sec>
      <sec id="article-30315.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The most common ECG abnormalities involving calcium channel blockers other than dihydropyridines are sinus bradycardia, variable degrees of atrioventricular blocks, bundle branch block, QT prolongation, and junctional rhythms. Dihydropyridines maintain normal sinus rhythm and can cause reflex sinus tachycardia.</p>
        <p>Hypotension and bradycardia, when progressive, can eventually lead to cardiogenic shock. Also, hyperglycemia is common with all subclasses of CCBs and can be a useful clinical marker for poisoning severity. Both of these&#x000a0;effects lead directly to metabolic acidosis.<xref ref-type="bibr" rid="article-30315.r10">[10]</xref><xref ref-type="bibr" rid="article-30315.r11">[11]</xref><xref ref-type="bibr" rid="article-30315.r12">[12]</xref> It is also common to develop mild hypokalemia and mild to severe hypocalcemia.<xref ref-type="bibr" rid="article-30315.r13">[13]</xref><xref ref-type="bibr" rid="article-30315.r2">[2]</xref></p>
        <p>Profound hypoperfusion and end-organ ischemia with a severe overdose can cause clinical evidence of end-organ failures like seizures, myocardial infarction, acute respiratory distress syndrome (ARDS), renal failure, bowel infarction and ischemia, and stroke.</p>
        <p>Reports of non-cardiogenic pulmonary edema with CCB overdose are few, and the mechanism is not well defined. Sudden rapid precapillary vasodilatation causing an increase in capillary hydrostatic pressure may explain it. Overaggressive administration of crystalloids in an attempt&#x000a0;to correct hypotension exacerbates the damage.<xref ref-type="bibr" rid="article-30315.r14">[14]</xref><xref ref-type="bibr" rid="article-30315.r15">[15]</xref></p>
      </sec>
      <sec id="article-30315.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The basic tenets of critically ill patient management remain focused on initial attention to airway, breathing, and circulations. Consider endotracheal intubation in patients with worsening signs and symptoms of toxicity due to the risk of rapid hemodynamic deterioration &#x02014; some advocate preadministration of atropine to offset vagally mediated hypotension and bradycardia during laryngoscopy.</p>
        <p>If rapid deterioration is not evident, the patient should still be on a continuous cardiac monitor with close, intensive care monitoring. History should focus on underlying medical conditions, type of formulation ingested (immediate vs. sustained release), co-ingestants, and time of ingestion. Obtain an ECG to identify conduction abnormalities. Atropine is mostly ineffective in severe CCB toxicity.<xref ref-type="bibr" rid="article-30315.r16">[16]</xref></p>
        <p>Use intravenous crystalloids during initial resuscitation while remaining cognizant of the risk of fluid overload with drug-induced inotropic failure. Therefore, dynamic assessment of fluid responsiveness with pulse pressure variability or stroke volume variability may be worthwhile.</p>
        <p>Finally, seek early consultation with a medical toxicologist or poison control center. Cardiology consultation is also prudent considering the likelihood of a transvenous pacemaker or intra-aortic balloon pump in severe overdose.</p>
        <p>Conventional decontamination measures like urinary alkalinization, hemodialysis, or hemofiltration are ineffective in CCB toxicity because of their large volume of distribution and lipophilic nature. Whole bowel irrigation is the mainstay of elimination in extended-release preparations.</p>
        <p>
<bold>Gastrointestinal Detoxification</bold>
</p>
        <p>Controversy exists regarding the utility of GI decontamination in early intervention patients. It should not take precedence over resuscitation and avoid it in unstable patients.<xref ref-type="bibr" rid="article-30315.r5">[5]</xref></p>
        <p>Administer activated charcoal in a dose of 1 gm/kg within 1&#x000a0;to 2 hours for maximum benefit.<xref ref-type="bibr" rid="article-30315.r16">[16]</xref> In a volunteer study, charcoal administration 2 hours after amlodipine ingestion reduced absorption by 49% compared with controls.<xref ref-type="bibr" rid="article-30315.r17">[17]</xref> The preferred method of decontamination is whole bowel irrigation (WBI). In large ingestion of sustained-release formulations, consider the use of activated charcoal for up to 4 hours and/or WBI. Activated charcoal can continue at a dose of 0.5 mg/kg every 2&#x000a0;to 4 hours, provided there are bowel sounds and no evidence of obstruction or perforation.<xref ref-type="bibr" rid="article-30315.r18">[18]</xref>&#x000a0;</p>
        <p>
<bold>Pharmacological Therapies</bold>
</p>
        <p>
<bold>Calcium</bold>
</p>
        <p>The rationale behind calcium administration is that increased extracellular concentration will promote calcium influx via unblocked L type calcium channels. However, responses are variable and suboptimal with severe toxicity. Calcium may improve hypotension and conduction disturbances but is less effective in the management of bradycardia. The optimum dose ranges from 4.5 to 95.3 mEq/L&#x000a0;based on reports, and there appears to be no identifiable dose-response relationship.<xref ref-type="bibr" rid="article-30315.r9">[9]</xref></p>
        <p>Calcium chloride contains triple the amount of elemental calcium on a weight to weight basis over calcium gluconate. (10% calcium chloride: 272mg elemental calcium or 13.6 mEq/1g ampule; 10% calcium gluconate: 90mg elemental calcium or 4.5 mEq/1g ampule). However, CaCl ideally should be administered via a central line because of the risk of skin necrosis on extravasation. The initial recommended dose is 10&#x000a0;to 20 ml of 10% calcium chloride (30&#x000a0;to 60 ml for calcium gluconate) with repeat boluses every 10&#x000a0;to 20 minutes for 3&#x000a0;or 4 additional doses if clinical response is inadequate.<xref ref-type="bibr" rid="article-30315.r18">[18]</xref>&#x000a0;Give boluses over 5 minutes as faster administration can cause hypotension, atrioventricular dissociation, and ventricular fibrillation.<xref ref-type="bibr" rid="article-30315.r19">[19]</xref><xref ref-type="bibr" rid="article-30315.r20">[20]</xref></p>
        <p>As the effect of calcium is transient, some centers recommend an infusion of calcium chloride titrating to effect and monitoring calcium levels, usually at 0.2&#x000a0;to 0.4 ml/kg/hour. Kerns et al. recommend monitoring calcium levels 30 minutes after starting infusion and every 2 hours during infusion.[19] Calcium gluconate is safe through a peripheral IV but requires higher volumes to achieve the same calcium dose. There have been cases of multiorgan failure with acute tubular necrosis, hepatic necrosis, splenic infarcts, and skin involvement from calciphylaxis related to over-aggressive use of calcium in the setting of CCB overdose. Most practitioners will administer calcium as an initial measure, but if toxicity reoccurs or worsens will switch to other interventions.</p>
        <p>
<bold>Insulin</bold>
</p>
        <p>Hyperinsulinemic euglycemia (HIE) has emerged as a potent therapy for severe calcium channel blocker toxicity. Experimental models show that CCB toxicity shifts myocardial substrate preference to carbohydrates from free fatty acids; thus, cardiac substrate delivery is impaired. CCBs also reduce insulin secretion, creates tissue insulin resistance, and interfere with glucose catabolism leading to lactic academia and metabolic acidosis. Insulin administered in such a setting helps to reverse all of those derangements of metabolism. Insulin has a direct positive inotropic effect that contributes to its clinical role here.<xref ref-type="bibr" rid="article-30315.r21">[21]</xref><xref ref-type="bibr" rid="article-30315.r22">[22]</xref></p>
        <p>The foundation of insulin used in CCB toxicity stems from several canine studies that showed an improvement in cardiac function and survival rate compared with placebo, epinephrine, glucagon, and calcium in verapamil overdose.<xref ref-type="bibr" rid="article-30315.r23">[23]</xref> A high dosage is usually necessary, leading to the obvious challenge of hypoglycemia and hypokalemia from the intracellular shift of potassium.</p>
        <p>The current insulin dosing recommendation is 1 Unit/kg regular insulin intravenous bolus followed by 1&#x000a0;to 10 U/kg/hour continuous infusion.<xref ref-type="bibr" rid="article-30315.r24">[24]</xref>&#x000a0;Higher doses are permissible in refractory cases. The goal of therapy is to achieve hemodynamic stability and withdrawal of vasoactive agents.</p>
        <p>Before the initiation of insulin therapy, check blood glucose and potassium. If less than 200 mg/dl and 2.5 meq/L, respectively, then dextrose and potassium supplementation are necessary.<xref ref-type="bibr" rid="article-30315.r24">[24]</xref></p>
        <p>
<bold>Methylene Blue</bold>
</p>
        <p>Methylene can counteract post coronary artery bypass vasoplegia (low systemic vascular resistance) by inhibiting guanylate cyclase, thus decreasing cyclic guanosine monophosphate (cGMP) and inhibiting nitric oxide synthesis.&#x000a0;It has successfully treated refractory cases of CCB overdose as an adjuvant to vasopressors and HIE therapy.<xref ref-type="bibr" rid="article-30315.r25">[25]</xref>&#x000a0;Bluish discoloration of urine, saliva, and skin is transient, lasting only 24 hours.</p>
        <p>
<bold>Lipid Emulsion Therapy</bold>
</p>
        <p>Intravenous lipid emulsion is an oil-in-water emulsion that creates a lipid phase within the plasma and pulls a lipid-soluble drug into the lipid phase in blood. Lipid emulsion infusion can&#x000a0;sequester intensely lipophilic drugs like verapamil and diltiazem and thus reduce their volume of distribution.</p>
        <p>There is also an enhanced metabolism theory that argues that the infusion of lipid emulsion provides a sustained fatty acid energy source to the myocyte under a toxic metabolic milieu.<xref ref-type="bibr" rid="article-30315.r26">[26]</xref></p>
        <p>The role and efficacy of lipid emulsion therapy in CCB toxicity are mostly based on animal studies and case reports and is therefore recommended only in refractory shock or severe toxicity unresponsive to conventional treatments.</p>
        <p>American Society of Regional Anesthesia recommends an initial bolus of 1.5 ml/kg of 20% lipid emulsion followed by 0.25&#x000a0;to 0.5 ml/kg/min over 30 minutes.<xref ref-type="bibr" rid="article-30315.r27">[27]</xref>&#x000a0;It can interfere with the analysis of blood glucose and magnesium, and therefore collect blood samples should before its infusion and monitor serum triglyceride levels.<xref ref-type="bibr" rid="article-30315.r28">[28]</xref></p>
        <p>Reported adverse effects of therapy in high doses and multiple administrations include acute pancreatitis, ARDS, interference with vasopressors, and fat overload syndrome inducing hepatosplenomegaly, seizures, fat embolism, and coagulopathy.<xref ref-type="bibr" rid="article-30315.r13">[13]</xref><xref ref-type="bibr" rid="article-30315.r29">[29]</xref></p>
        <p>
<bold>Glucagon</bold>
</p>
        <p>Glucagon secreted from alpha cells of the pancreas act through activation of adenylate cyclase via G proteins resulting in a positive chronotropic and inotropic effect.<xref ref-type="bibr" rid="article-30315.r30">[30]</xref>&#x000a0;Bailey et al. showed an improvement in heart rate, cardiac output, and reversal of AV blocks in animal models of CCB overdose using glucagon.<xref ref-type="bibr" rid="article-30315.r31">[31]</xref> A bolus of 5&#x000a0;to 10 mg over 1&#x000a0;to 2 minutes is an appropriate initial dose. The effects of administration are clear within 1&#x000a0;to 3 minutes and last 10&#x000a0;to 15 minutes. Because of the short duration of action, an intravenous infusion of 2&#x000a0;to 10 mg/hour should follow the initial bolus.<xref ref-type="bibr" rid="article-30315.r31">[31]</xref><xref ref-type="bibr" rid="article-30315.r32">[32]</xref></p>
        <p>It is an emetic and nausea; vomiting can occur with bolus doses above 50 micrograms/kg. It can also induce hyperglycemia, hypokalemia, and ileus.</p>
        <p>
<bold>Catecholamines</bold>
</p>
        <p>Refractory hypotension and shock may result from both cardiac depression and loss of peripheral vascular resistance in severe CCB toxicity. Catecholamine infusion may become necessary in such a setting in addition to the other pharmacological therapies. There hasn&#x02019;t been a single established agent of choice between dopamine, norepinephrine, epinephrine, or even dobutamine. The optimal agent of choice is, therefore, unclear. Thus, the mechanism of shock and assessment of cardiac performance should guide decisions. The Society of Critical Care Medicine consensus guidelines recommends using norepinephrine or epinephrine, with preferential use of norepinephrine in the presence of vasodilatory shock. (Level 1D recommendation).<xref ref-type="bibr" rid="article-30315.r33">[33]</xref>&#x000a0;Because of inconsistent hemodynamic improvement in the case series, the workgroup suggested against the use of dopamine.<xref ref-type="bibr" rid="article-30315.r16">[16]</xref><xref ref-type="bibr" rid="article-30315.r9">[9]</xref></p>
        <p>
<bold>Other Agents</bold>
</p>
        <p>Phosphodiesterase inhibitors like milrinone may provide inotropic support in decompensated cardiogenic shock. Similarly, levosimendan is an inotropic agent that enhances myofilament response to calcium and increases myocardial contraction and could, therefore, be beneficial in verapamil intoxication.</p>
        <p>
<bold>Non-Pharmacological Aspects Of Treatment</bold>
</p>
        <p>As mentioned before, management and monitoring in an ICU setting are essential with the availability of advanced hemodynamic interventions like transvenous pacers, intra-aortic balloon pump, or extracorporeal membrane oxygenation if it is necessary.</p>
        <p>Consider incremental increases in the dose of high dose insulin infusion therapy and veno-arterial extracorporeal membrane oxygenation (VA&#x02013;ECMO) for the patient with refractory shock.<xref ref-type="bibr" rid="article-30315.r34">[34]</xref><xref ref-type="bibr" rid="article-30315.r35">[35]</xref></p>
        <p>Once stabilized, arrangements for appropriate psychiatric evaluation and behavioral health consultation may be appropriate.</p>
      </sec>
      <sec id="article-30315.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Because of their similarity of end-organ affinity, pharmacological action, and target patients, beta-blockers are the most common confounders. Compared to CCBs, beta-blockers are less likely to cause hyperglycemia in adult patients.<xref ref-type="bibr" rid="article-30315.r36">[36]</xref></p>
        <p>However, an initial presentation with bradycardia and hypotension should prompt consideration of a wide array of pharmacological agents, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Beta-blocker toxicity</p>
          </list-item>
          <list-item>
            <p>Tricyclic antidepressant toxicity</p>
          </list-item>
          <list-item>
            <p>Digoxin toxicity</p>
          </list-item>
          <list-item>
            <p>Clonidine overdose</p>
          </list-item>
          <list-item>
            <p>Sedative-hypnotic toxicity</p>
          </list-item>
          <list-item>
            <p>Opiate overdose</p>
          </list-item>
          <list-item>
            <p>Organophosphate poisoning</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30315.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis beyond the initial toxicity depends upon the magnitude of ingestion, the severity of toxidrome, and the extent of organ dysfunction.</p>
        <p>Poor prognostic factors include</p>
        <list list-type="bullet">
          <list-item>
            <p>Advanced age</p>
          </list-item>
          <list-item>
            <p>Preexisting impairment of cardiac function</p>
          </list-item>
          <list-item>
            <p>Multi-organ failure</p>
          </list-item>
          <list-item>
            <p>Refractory shock requiring salvage measures like extracorporeal membrane oxygenation (ECMO)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30315.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications range from the poisoning itself to the untoward effects of life-saving interventions.</p>
        <p>
<bold>Complications From Toxicity</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Refractory cardiogenic and distributive shock</p>
          </list-item>
          <list-item>
            <p>Acute respiratory distress syndrome (ARDS)</p>
          </list-item>
          <list-item>
            <p>Severe hypoperfusion and resultant end-organ injury like ischemic bowel, myocardial infarction, acute tubular necrosis, limb necrosis</p>
          </list-item>
          <list-item>
            <p>Pulseless electrical activity with cardiac arrest (PEA)</p>
          </list-item>
        </list>
        <p>
<bold>Complications From Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiorgan failure from calciphylaxis with overaggressive calcium infusion</p>
          </list-item>
          <list-item>
            <p>Hypokalemia and hypoglycemia with HIET</p>
          </list-item>
          <list-item>
            <p>ARDS, hypertriglyceridemia, pancreatitis, and fat overload syndrome with lipid emulsion therapy</p>
          </list-item>
          <list-item>
            <p>Nausea, vomiting, ileus, and hypokalemia with glucagon</p>
          </list-item>
          <list-item>
            <p>Arterial and venous thrombosis and limb ischemia with interventions like ECMO</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30315.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Calcium channel blockers are a medication class used to treat a wide range of clinical conditions like high blood pressure, high and irregular heart rate, bluish discoloration and spasms of fingers, or headaches. Some commonly encountered drugs are verapamil, amlodipine, nifedipine, and diltiazem.</p>
        <list list-type="bullet">
          <list-item>
            <p>Like most other medications, when taken beyond the appropriate recommended dosage, they can have untoward toxicities with a wide range of complications that can even be fatal.</p>
          </list-item>
          <list-item>
            <p>Sometimes preexisting derangement of metabolism or interaction with other drugs can result in toxic accumulation in the body.</p>
          </list-item>
          <list-item>
            <p>Any concern for excessive ingestion or early onset of abnormal symptoms should immediately prompt a call for help.</p>
          </list-item>
          <list-item>
            <p>If mildly symptomatic or asymptomatic, it is always wise to ensure safety. Help is readily available through the poison control center helpline. In the US, call 800-222-1222, available 24/7.</p>
          </list-item>
          <list-item>
            <p>If symptomatic with dizziness, lightheadedness, confusion, nausea, an immediate visit to the emergency department can save lives. Time is of the essence in this situation.</p>
          </list-item>
          <list-item>
            <p>Beyond an acute episode, ensure the safety of the home environment, supervise medication administration in the elderly, and seek psychiatric help in individuals with suicidal intent or depression.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30315.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Patients in whom even mild intoxication is suspected should be observed in a monitored setting for at least 12 hours with immediate-release formulation ingestion to 24 hours for sustained release formulations.</p>
          </list-item>
          <list-item>
            <p>Evaluating and differentiating between negative inotropy and low systemic vascular resistance is helpful in the selection of appropriate vasoactive agents. (inotropes vs. vasopressors like norepinephrine)</p>
          </list-item>
          <list-item>
            <p>Urgent and time-sensitive use of gastrointestinal decontamination (if brought in early), intravenous crystalloids, calcium, vasopressors, and HIET therapy is warranted, often in conjunction&#x000a0;with each other.</p>
          </list-item>
          <list-item>
            <p>It is easy to focus on the distractions of the specific therapeutic modalities and their administration, but the initial focus should be on the basics of resuscitation in an emergency - that of securing circulation, airway, and breathing first.</p>
          </list-item>
          <list-item>
            <p>Because of their affinity to plasma proteins, high hepatic first pass, and a large volume of distribution, hemodialysis or hemofiltration are not effective.</p>
          </list-item>
          <list-item>
            <p>In refractory cases of cardiogenic shock, consider an incremental increase in the dose of HIET along with advanced hemodynamic interventions like transvenous pacing and VA - ECMO.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30315.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Between 2000 to 2010, US residents in the age group of 50&#x000a0;to 54 experienced the highest population growth. With this increasing shift towards more elderly Americans, it is logical to expect increased use of cardiovascular medication and unintended or intended drug toxicities. While home monitoring of asymptomatic patients in the setting of mild calcium channel blocker overdose may be safe, patients or caregivers need education with relevant knowledge about the drugs as well as resources for poison control center helplines. Likewise, any evidence of symptoms even early should not be neglected and promptly evaluated in the emergency room setting. The presence of certain risk factors even in asymptomatic individuals should prompt an aggressive approach to care. That includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric or geriatric age groups</p>
          </list-item>
          <list-item>
            <p>Poor cardiac&#x000a0;health</p>
          </list-item>
          <list-item>
            <p>A suspected overdose of multiple medications, particularly another cardio depressant drug</p>
          </list-item>
          <list-item>
            <p>Large dose</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Ingestion of sustained-release tablets</p>
          </list-item>
        </list>
        <p>The management of CCB toxicity&#x000a0;is with an interprofessional team that includes an emergency department physician, cardiologist, toxicologist, nurse practitioner, pharmacologist, internist, and specialty-trained emergency and trauma nurses.&#x000a0;Pharmacists should evaluate medications prescribed, drug-drug interactions, and patient compliance and communicate with the team. Specialty trained nurses assist with monitoring the patient and report issues to the team. This approach will lead to improved patient outcomes. [Level 5]</p>
        <p>Finally, beyond the period of acute stabilization and management, the establishment of home safety parameters, social work support, and psychiatry consultation and support for intentional suicidal overdoses are critical determinants for an&#x000a0;optimum outcome.</p>
      </sec>
      <sec id="article-30315.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30315&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30315">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/calcium-channel-blocker-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30315">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30315/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30315">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30315.s16">
        <title>References</title>
        <ref id="article-30315.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dolphin</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Voltage-gated calcium channels: their discovery, function and importance as drug targets.</article-title>
            <source>Brain Neurosci Adv</source>
            <year>2018</year>
            <month>Oct</month>
            <day>02</day>
            <volume>2</volume>
            <pub-id pub-id-type="pmid">30320224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salhanick</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Management of calcium channel antagonist overdose.</article-title>
            <source>Drug Saf</source>
            <year>2003</year>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>65</fpage>
            <page-range>65-79</page-range>
            <pub-id pub-id-type="pmid">12534324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cantilena</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rumack</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>910</fpage>
            <page-range>910-41</page-range>
            <pub-id pub-id-type="pmid">22165864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramoska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blocker toxicity.</article-title>
            <source>Ann Emerg Med</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>649</fpage>
            <page-range>649-53</page-range>
            <pub-id pub-id-type="pmid">2344082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramoska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borys</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment.</article-title>
            <source>Ann Emerg Med</source>
            <year>1993</year>
            <month>Feb</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-200</page-range>
            <pub-id pub-id-type="pmid">8427431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kline</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The diabetogenic effects of acute verapamil poisoning.</article-title>
            <source>Toxicol Appl Pharmacol</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>145</volume>
            <issue>2</issue>
            <fpage>357</fpage>
            <page-range>357-62</page-range>
            <pub-id pub-id-type="pmid">9266809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Proano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>RY</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blocker overdose.</article-title>
            <source>Am J Emerg Med</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>444</fpage>
            <page-range>444-50</page-range>
            <pub-id pub-id-type="pmid">7605536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herrington</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Insley</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Weinmann</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Nifedipine overdose.</article-title>
            <source>Am J Med</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>344</fpage>
            <page-range>344-6</page-range>
            <pub-id pub-id-type="pmid">3740090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>da Silva</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>de Melo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jorge Filho</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Verapamil acute self-poisoning.</article-title>
            <source>Clin Toxicol</source>
            <year>1979</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-7</page-range>
            <pub-id pub-id-type="pmid">466977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofer</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Tenholder</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options.</article-title>
            <source>Am J Med</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>431</fpage>
            <page-range>431-8</page-range>
            <pub-id pub-id-type="pmid">8213877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>YZ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Verapamil overdose and severe hypocalcemia.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1992</year>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>309</fpage>
            <page-range>309-11</page-range>
            <pub-id pub-id-type="pmid">1588680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Epid</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Sayer</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Relative toxicity of beta blockers in overdose.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1996</year>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-8</page-range>
            <pub-id pub-id-type="pmid">8667464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howarth</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blocking drug overdose: an Australian series.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>1994</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-6</page-range>
            <pub-id pub-id-type="pmid">7909677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bond</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review.</article-title>
            <source>Ann Emerg Med</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-86</page-range>
            <pub-id pub-id-type="pmid">11867980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laine</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kivist&#x000f6;</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Laakso</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Neuvonen</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-33</page-range>
            <pub-id pub-id-type="pmid">9056049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thanacoody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Troutman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>H&#x000f6;jer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hoppu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Erdman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bedry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-12</page-range>
            <pub-id pub-id-type="pmid">25511637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Beta-blocker and calcium channel blocker toxicity.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>1994</year>
            <month>May</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>365</fpage>
            <page-range>365-90</page-range>
            <pub-id pub-id-type="pmid">7910555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlon</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Howland</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Goldiner</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Bertoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Turnbull</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of calcium administration. Report of two cases.</article-title>
            <source>Arch Surg</source>
            <year>1978</year>
            <month>Jul</month>
            <volume>113</volume>
            <issue>7</issue>
            <fpage>882</fpage>
            <page-range>882-5</page-range>
            <pub-id pub-id-type="pmid">678101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chin</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Garmel</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Harter</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Development of ventricular fibrillation after intravenous calcium chloride administration in a patient with supraventricular tachycardia.</article-title>
            <source>Ann Emerg Med</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>416</fpage>
            <page-range>416-9</page-range>
            <pub-id pub-id-type="pmid">7864486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kline</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Insulin is a superior antidote for cardiovascular toxicity induced by verapamil in the anesthetized canine.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>267</volume>
            <issue>2</issue>
            <fpage>744</fpage>
            <page-range>744-50</page-range>
            <pub-id pub-id-type="pmid">8246150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epstein</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Skelton</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Adenyl cyclase and cyclic AMP. Biochemical links in the regulation of myocardial contractility.</article-title>
            <source>Circulation</source>
            <year>1971</year>
            <month>Mar</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>437</fpage>
            <page-range>437-50</page-range>
            <pub-id pub-id-type="pmid">4322713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2003</year>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>595</fpage>
            <page-range>595-602</page-range>
            <pub-id pub-id-type="pmid">14514004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Spyres</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manini</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Toxin-induced cardiovascular failure.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-102</page-range>
            <pub-id pub-id-type="pmid">24275170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kute</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Goplani</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Gumber</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Vanikar</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of refractory hypotension, noncardiogenic pulmonary edema and acute kidney injury after an overdose of amlodipine.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>182</fpage>
            <page-range>182-4</page-range>
            <pub-id pub-id-type="pmid">22013313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sami Karti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ulusoy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yandi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nd&#x000fc;z</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ko&#x0015f;ucu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ratip</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Non-cardiogenic pulmonary oedema in the course of verapamil intoxication.</article-title>
            <source>Emerg Med J</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>458</fpage>
            <page-range>458-9</page-range>
            <pub-id pub-id-type="pmid">12205007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montiel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gougnard</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hantson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Diltiazem poisoning treated with hyperinsulinemic euglycemia therapy and intravenous lipid emulsion.</article-title>
            <source>Eur J Emerg Med</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-3</page-range>
            <pub-id pub-id-type="pmid">21088599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunbaum</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gilfix</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Analytical interferences resulting from intravenous lipid emulsion.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>9</issue>
            <fpage>812</fpage>
            <page-range>812-7</page-range>
            <pub-id pub-id-type="pmid">23075253</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engebretsen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Kaczmarek</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holger</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-83</page-range>
            <pub-id pub-id-type="pmid">21563902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anseeuw</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cantrell</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Gilchrist</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Hantson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kerns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lalibert&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Muscedere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sinuff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rieder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000e9;garbane</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults.</article-title>
            <source>Crit Care Med</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>e306</fpage>
            <page-range>e306-e315</page-range>
            <pub-id pub-id-type="pmid">27749343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>UN</given-names>
              </name>
            </person-group>
            <article-title>Insulin: an endogenous cardioprotector.</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>375</fpage>
            <page-range>375-83</page-range>
            <pub-id pub-id-type="pmid">14508150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eiger</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Hyperinsulinemic euglycemia therapy for verapamil poisoning: a review.</article-title>
            <source>Am J Crit Care</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>498</fpage>
            <page-range>498-503</page-range>
            <pub-id pub-id-type="pmid">17724247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aggarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kupfer</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seneviratne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tessler</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Methylene blue reverses recalcitrant shock in &#x003b2;-blocker and calcium channel blocker overdose.</article-title>
            <source>BMJ Case Rep</source>
            <year>2013</year>
            <month>Jan</month>
            <day>18</day>
            <volume>2013</volume>
            <pub-id pub-id-type="pmid">23334490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sim</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>FT</given-names>
              </name>
            </person-group>
            <article-title>A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose.</article-title>
            <source>J Med Toxicol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-9</page-range>
            <pub-id pub-id-type="pmid">18338308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sebe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di&#x0015f;el</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>A&#x000e7;&#x00131;kal&#x00131;n Akp&#x00131;nar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karako&#x000e7;</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Role of intravenous lipid emulsions in the management of calcium channel blocker and &#x003b2;-blocker overdose: 3 years experience of a university hospital.</article-title>
            <source>Postgrad Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>127</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-24</page-range>
            <pub-id pub-id-type="pmid">25684131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Heard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Foran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koyfman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intravenous lipid emulsion in the emergency department: a systematic review of recent literature.</article-title>
            <source>J Emerg Med</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-97</page-range>
            <pub-id pub-id-type="pmid">25534900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30315.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Franken</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Delayed-onset seizure and cardiac arrest after amitriptyline overdose, treated with intravenous lipid emulsion therapy.</article-title>
            <source>Pediatrics</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>130</volume>
            <issue>2</issue>
            <fpage>e432</fpage>
            <page-range>e432-8</page-range>
            <pub-id pub-id-type="pmid">22753554</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
